# Calcium supplementation of the diet-II

## Not justified by present evidence

Last week we looked at the way diverging views on the role of calcium had arisen. This week we conclude our re-examination of the evidence with a look at the part calcium plays in the menopause, in the elderly, and in fractures.

### Skeletal loss at the menopause

There is overwhelming evidence that bone loss in women is associated with gonadal failure at the menopause. In addition, oestrogens prevent bone loss and the risk of subsequent fracture in perimenopausal women.<sup>17</sup> The precise action of oestrogens on bone is not, however, certain.

The menopause is associated with increased calcium losses in urine and reduced intestinal absorption of calcium. Low concentrations of calcitriol (1,25-dihydroxyvitamin D<sub>3</sub>) have been found by some but not all investigators.<sup>8-10</sup> Heaney et  $al^{11}$  have estimated calcium requirements in many middle aged women by balance studies undertaken without large changes in the customary dietary intake of calcium and therefore without the same methodological flaws of earlier work in older women.<sup>13</sup> They found that women with the lower dietary intakes of calcium were in greater negative balance and that there was a positive correlation between calcium intake and balance. Regression analysis showed a mean requirement of greater than 750 mg daily and hence a calculated recommended daily allowance of 1150-1350 mg.14 These studies in menopausal women show that about three quarters of the women in the United States and Britain, and a far greater proportion throughout the world, have a calcium intake below the computed American allowance.

This interpretation provides a rationale for providing calcium supplements or stimulating its absorption with vitamin D metabolites. It has an intuitive appeal, but the logic is similar to that which might lead doctors to give ground up brains for dementia. The argument also depends critically on whether reduced intestinal absorption of calcium is a cause or a consequence of osteoporosis. Those favouring its causal role argue that oestrogens directly stimulate the production of calcitriol; deficiency at the menopause thus results in deficiency of calcitriol and malabsorption of calcium thereby aggravating the osteoporotic process. The converse view is that lack of oestrogen induces bone loss and an infusion of the extracellular fluid with calcium. This in turn induces a series of homoeostatic responses that offset the hypercalcaemic challenge of osteoporosis.

These opposing views are difficult to resolve from population studies.<sup>14</sup> If lack of oestrogen induces bone loss then the changes in balance (and apparent requirement) in perimenopausal women are the consequence and not the cause of osteoporosis. The danger of overinterpreting calcium requirements from balance studies is well illustrated by the bone loss of immobilisation, which gives rise to a negative calcium balance; at any given dietary intake the apparent requirement for calcium increases. The conclusion that an increased dietary intake of calcium offsets these losses is clearly misleading and not supported by experimental observation.<sup>15</sup> Assuming that a low intestinal absorption and negative

moduling that a low intestinal absorption and

calcium balance were the consequences of osteoporosis, we would expect that the apparent requirement for calcium would be similar irrespective of the dietary intake. There does seem to be a direct and linear relation between dietary intake and calcium balance in perimenopausal women. The slope of this regression differs from unity and from that of normal subjects-such that women with lower intakes of calcium have the higher apparent requirement.11 16 17 This observation forms the major thrust of arguments for giving perimenopausal women large amounts of calcium to offset perimenopausal bone loss.<sup>14</sup> The slope describing the relation between calcium intake and apparent calcium requirements is, however, the same in women before and after the menopause (fig 1).12 This suggests that the menopause is associated with a finite fall in calcium absorption irrespective of dietary intake and argues against calcium deficiency causing perimenopausal bone loss.




FIG 1—Relation between external balance and dietary intake of calcium in 207 untreated premenopausal and 41 untreated postmenopausal women (data from Heaney et  $al^{n_2}$ )

Ironically the misinterpreted Yugoslavian data discussed last week throws light on this problem as they clearly show that cortical bone loss occurred at an equal rate in both communities—that with a standard intake of calcium and that taking double the amount.<sup>18</sup> Similar conclusions have been made in other large surveys,<sup>19 20</sup> and more recently the rates of cortical and trabecular bone loss at various sites, including the lumbar spine, have been shown to be independent of habitual calcium intake.<sup>21 22</sup>

Even if dietary intake of calcium does not influence bone loss at the menopause large calcium supplements might reduce perimenopausal bone loss. In Denmark 103 women were given a 400 mg calcium supplement to increase their daily intake to 1-2 g.<sup>23</sup> This had no effect on bone loss in the distal forearm over two years. In other well controlled studies large calcium supplements (1500-2000 mg daily) had no measurable effect on trabecular bone loss of the forearm or spine and only small effects at cortical sites.<sup>7 24</sup> In contrast, bone loss was prevented by oestrogens. Increasing the efficiency of calcium absorption with derivatives of vitamin D also has no consistent effect on menopausal bone loss.<sup>5 25</sup>

TABLE I – Details of controlled studies examining effects of calcium in elderly (not perimenopausal) women

			No of patients*						
Age (years)	Years since menopause	Population	Enrolled	Completing treatment	Placebo given	Random allocation	Prospective study	Duration (months)	Comments
51	7.0	Healthy women	24	24	No	No	Yes	24	
45-70		Healthy women	16	13	No	Yes	Yes	24	
57	7.7	Healthy women	22	22	No	Yes	Yes	24	
64	18.1	Crush fracture	20	20	No	. No	Yes	30	Variable duration
25-82		"Osteoporosis"	94	94	No	No	No	18-56	Retrospective controls
80		Healthy women	12	12	No	No	Yes	36	
80		Healthy women	35	21	Yes	Yes	Yes	36	
60		Colles fracture	20	19	Yes	Yes	Yes	12	
	(years) 51 45-70 57 64 25-82 80 80	(years) menopause 51 7⋅0 45⋅70 57 7⋅7 64 18⋅1 25⋅82 80 80	(years)menopausePopulation517·0Healthy women45-70Healthy women577·7Healthy women6418·1Crush fracture25-82"Osteoporosis"80Healthy women80Healthy women	Age (years)Years since menopausePopulationEnrolled517.0Healthy women2445-70Healthy women16577.7Healthy women226418.1Crush fracture2025-82"Osteoporosis"9480Healthy women1280Healthy women35	Age (years)Years since menopausePopulationCompleting Enrolled517.0Healthy women Healthy women242445-70Healthy women1613577.7Healthy women22226418.1Crush fracture "Osteoporosis"202025-82"Osteoporosis"949480Healthy women121280Healthy women3521	Age (years)Years since menopausePopulationCompleting EnrolledPlacebo given517·0Healthy women2424No45-70Healthy women1613No577·7Healthy women2222No6418·1Crush fracture2020No25-82"Osteoporosis"9494No80Healthy women1212No80Healthy women3521Yes	Age (years)Years since menopausePopulationCompleting EnrolledPlacebo reatmentRandom allocation517·0Healthy women Healthy women2424NoNo45-70Healthy women Healthy women1613NoYes577·7Healthy women Crush fracture2020NoNo25-82"Osteoporosis"9494NoNo80Healthy women Healthy women1212NoNo80Healthy women Healthy women3521YesYes	Age (years)Years since menopausePopulationCompleting EnrolledPlacebo givenRandom allocationProspective study517·0Healthy women Healthy women2424NoNoYes45-70Healthy women Healthy women1613NoYesYes577·7Healthy women Crush fracture2020NoNoYes6418·1Crush fracture 'Osteoporosis''2020NoNoYes80Healthy women1212NoNoYes80Healthy women3521YesYesYes	Age (years)Years since menopausePopulationCompleting EnrolledPlacebo treatmentRandom allocationProspective studyDuration (months)517·0Healthy women Healthy women2424NoNoYes2445-70Healthy women Healthy women1613NoYesYes24577·7Healthy women Learthy the crush fracture 'Osteoporosis''2020NoNoYes3025-82''Osteoporosis''9494NoNoNoYes3680Healthy women Healthy women1212NoNoYes3680Healthy women3521YesYesYes36

\*Women in treated group.

TABLE II - Results of controlled studies of calcium supplements in elderly (not perimenopausal) women

Study	Dose (mg/day)	Dietary calcium (mg/day)*	Assessment	Site	Result compared with controls	Significance
Horsman et al <sup>2</sup>	800	Not given	{ SPA SPA CW	Distal ulna Distal radius Metacarpals	Decreased loss Decreased loss No difference	p<0.025 NS
Recker and Heaney*	800	1500	{ Balance† { SPA CW	Distal forearm Metacarpals	Improved No difference No difference	NS
Recker et al*	1040	1543	CW SPA XRD Kinetic†	Metacarpals Distal radius Distal phalanx	No difference Loss decreased Loss decreased Decreased turnover	NS p<0.05 p<0.01
Nordin et al*	1200		CW Balance Fracture	Metacarpals Spine score	Decreased loss Improved Less deterioration	$NS \\ p=0.02 \\ NS$
Smith et al <sup>47</sup>	1140-1200	Not given	XRD	Metacarpal	Decrease	p<0.01
Albanese et al**	750	1200	XRD	Second phalanx	Increased density	p<0.001
Smith et al**	750	Not given	SPA	Proximal third of radius	Gain of bone	$\dot{p} = 0.05$
Lamke et al**	800	Not given	{ XRD { XRD	Femoral neck Femoral shaft	Increased density Increased density	NS NS

CW=Cortical width; XRD=x ray densitometry; SPA=single photon absorptiometry. \*With calcium supplements. †After one year.

Further insight into the comparative importance of oestrogens, exercise, and calcium on menopausal bone loss hence comes from studies of bone loss in two groups of young amenorrhoeic women—one being those with anorexia nervosa and the other being marathon runners. Both had reduced skeletal mass, but the runners had more than adequate exercise and an adequate calcium intake.<sup>26 27</sup> This suggests that dietary measures and exercise are not alternatives to oestrogens in maintaining skeletal mass at the time of gonadal failure.

#### Skeletal losses in the elderly

Bone loss continues throughout later life, but the rate of bone loss falls with advancing years.<sup>19</sup> The questions arise whether calcium intake affects the rate of bone loss in women long past the menopause and whether high intakes may either prevent this loss or rebuild bone. Many studies of calcium requirement have been undertaken in elderly people using balance techniques.<sup>16 28-31</sup> As expected, none showed a mean apparent requirement of less than 800 mg, but none may be interpreted with confidence. Other surveys of elderly people have shown that patients with osteoporosis took less calcium in their diets than those without osteoporosis.<sup>17 28 32 33</sup> One obvious interpretation would be that if such patients had taken more calcium they would have been spared osteoporosis. The alternative view that patients with osteoporosis were smaller or took less exercise and so selected diets of lower energy and calcium content seems not to have been considered. Yet there is no convincing evidence that the rate of bone loss in the elderly varies with dietary intake of calcium, whereas it is modified by exercise.<sup>34</sup> In addition, there is no evidence for a relation between dietary calcium and the incidence of osteoporotic fractures.<sup>35 36</sup> Indeed, hip fractures are less common in populations with low dietary intakes of calcium.<sup>37</sup>

Various problems confound our ability to assess the therapeutic effects of calcium and other agents on the natural course of senile bone loss. Firstly, osteoporosis is a heterogeneous disorder: in some patients the bone loss is predominantly trabecular whereas in others it is cortical.<sup>38</sup> Thus measurements of cortical bone to assess treatment may not reflect changes in trabecular bone. Moreover, there are large differences in the turnover of trabecular tissue at different skeletal sites so that observations made at one site with one technique may not reflect changes at another with the same or different techniques.<sup>39-41</sup>

Many studies have examined the effects of calcium supplements on bone mass or calcium balance in elderly people. Early observers showed that calcium supplements led to positive calcium balance in patients with osteoporosis. It was assumed that this increased skeletal mass and that the avidity of the skeleton was enhanced in this disorder.<sup>16,28,30,42</sup> Therapeutic claims based on these short term balance studies suffer from the same drawbacks as estimates of dietary requirement. Indeed, if acute changes in metabolic balance represented a new steady state then dietary calcium supplements of 1-4 g daily might be expected to increase skeletal mass by more than 10% yearly, a view not consistent with subsequent reports on skeletal mass.

Nevertheless, several controlled studies show that calcium supplements decrease the rate of bone loss in elderly women (tables I and II).<sup>3 5 43-48</sup>

Increases in skeletal mass at regional sites have also been

reported after calcium supplements.<sup>43 48 49</sup> This effect may result from several mechanisms: increased energy consumption<sup>49</sup> or changes induced in remodelling of bone<sup>50</sup> and calcium accretion at quiescent bone surfaces. The suppression of the secretion of parathyroid hormone by large calcium loads should decrease activation of new remodelling sites, but early during treatment bone formation continues at previously existing remodelling sites and bone mass increases transiently. As bone turnover is slow, bone mass may increase transiently for several years before a new steady state is achieved.<sup>41 50</sup> This transient state probably explains why almost no treatment for established osteoporosis has been shown to be ineffective.

Notwithstanding this, if a progressive increase in skeletal mass cannot be attained then at least the rate of loss may be attenuated because new bone formed in the adult is deposited principally at sites of previous resorption. Thus at each remodelling site a finite volume of bone is resorbed (over days) and in patients with osteoporosis a lesser amount is formed (over months). About 6 mmol (250 mg) calcium is resorbed daily and about 5 mmol put back by bone formation at the many remodelling sites. A net daily deficit of 1 mmol calcium is equivalent to a bone loss of about 1% a year. If bone turnover is decreased the number of remodelling sites decreases but the imbalance between formation and resorption at each site persists. Thus if bone turnover is decreased by half bone loss is reduced from 1% to 0.5% yearly. There is good evidence that the turnover of bone decreases in elderly patients given calcium supplements,446 and thus the rate of change of bone mass with therapeutic intervention is unlikely to be linear.

Derivatives of vitamin D that enhance intestinal absorption of calcium have shown fewer consistent effects than calcium supplements alone in elderly patients.<sup>45 51-53</sup> Thus the balance of evidence suggests that diets enriched with calcium do not provide a treatment for osteoporosis by restoring skeletal mass. At best they decrease the rate of bone loss in elderly women rather than in perimenopausal women. This effect is not necessarily negligible as a decrease in the rate of bone loss increases the time taken for a patient to reach a "fracture threshold." The beneficial effects of calcium supplements have, however, been reported mainly in women with advanced osteoporosis who may already have reached a fracture threshold. Furthermore, inhibition of bone turnover may decrease skeletal losses but increase the turnover time of bone and so delay the repair of damage caused by fatigue. Appreciable decreases in bone turnover seem to increase the risk of fracture despite the maintenance of skeletal mass.4154 The question thus arises whether the beneficial effects on the rate of bone loss alter fracture frequency.

#### Effect of calcium on fracture frequency

World wide there is a direct relation between calcium intake and frequency of hip fracture (fig 2). The incidences of fractures of the femoral neck and Colles fractures in Europe are rising at a rate greater than may be accounted for by the aging of the population.<sup>54-58</sup> The cause for these increases are unknown but might be related to changes in energy consumption: in Britain body weights have not changed over the past 20 years but overall food consumption has decreased by about a fifth, suggesting a more sedentary lifestyle. The increase does not seem to depend on calcium intake as the incidence of fractures is increasing equally in Malmö and Oslo, although calcium intake is much higher in Malmö because of its hard water (G Samsioe, personal communication).

As calcium supplements in elderly people decrease bone

Two studies have reported the beneficial effects of calcium on the frequency of fractures,<sup>45 61</sup> but in both the design of the trial was flawed.<sup>41</sup> Attempts to increase the intestinal availability of calcium with derivatives of vitamin D have not shown a consistently beneficial effect on the frequency of fractures.<sup>51-53 62 63</sup>

Ironically, whether calcium alone prevents fractures may never be answered as, in the United States at least, randomised studies of treating osteoporosis without calcium are now considered to be unethical.<sup>64</sup>

#### Conclusions

Dietary calcium deficiency is rare in man. Hence arguments about recommended daily allowances are misleading and largely irrelevant for public health. Like Garn,<sup>10</sup> we have come to doubt that adult bone loss is retribution for failing to obtain the recommended daily allowances of calcium. All normal diets contain sufficient calcium, and the excess of calcium present in milk drinkers is not absorbed, which protects them against calcium toxicity.

Despite these considerations calcium supplements might modify the course of disease. Thus in patients with hypoparathyroidism or calcium deficiency accompanying rickets calcium supplements help to restore calcium balance and skeletal metabolism to normal. But the evidence that supplemental calcium increases peak bone mass or decreases the incidence of fractures in elderly people is not convincing. This does not mean that it has no effect, only that an effect has yet to be convincingly shown. Any effect is likely to be small but may not be insignificant: a drug that was only 1% more effective than placebo in reducing the incidence of fractures would prevent more than 1000 fractures a year in Britain. This suggests that even if drugs or dietary manipulations had little efficacy they could still assume considerable importance




FIG 2—Relation between age adjusted incidence of hip fracture and dietary intake of calcium in several parts of the world (from Hegsted<sup>57</sup>)

as general health measures. Nevertheless, the argument that, with some exceptions, calcium supplements do little harm and may do some good serves neither the public nor the scientific community when the relative risks and benefits remain undetermined. To healthy citizens who may be worrying about whether their diet has sufficient calcium to meet their needs and whether they should take a supplement we commend Shakespeare's words at the beginning of the first part of this review and advise that they do not need a calcium supplement.

JAK is supported by a programme grant from the Medical Research Council.

Reader.

J A KANIS

Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, Sheffield S10 2RX

#### **R PASSMORE**

Retired Reader in Physiology, Edinburgh EH10 4RX

- Paganini-Hill A, Ross RK, Gerkins VR, Henderson BE, Arthur M, Mack TM. Menopausal estrogen therapy and hip fractures. Ann Intern Med 1981;95:28-31.
   Horsman A, Gallacher JC, Simpson M, Nordin BEC. Prospective trial of oestrogen and calcium in postmenopausal women. Br Med 7 1977;ii:789-92.
   Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomised

- Women, Lancet 1980; ii:1151-4.
  Recker RR, Saville PD, Heaney RP. Effect of estrogens and calcium carbonate on bone loss in postmenopausal women. Ann Intern Med 1977;87:649-55.
  Christiansen C, Christiansen MS, Rodbro P, Hagen C, Transbol I. Effect of 1,25-dihydroxyvitamin
- D in itself or combined with hormone treatment in preventing postmenopausal osteoporosis. Eur J Clin Invest 1981;11:305-9
- *J Clin Invest* 1981;11:305-9.
  Hutchinson TA, Polansky SM, Feinstein AR. Post-menopausal oestrogens protect against fractures of hip and distal radius. *Lancet* 1979;ii:705-9.
  Ettinger B, Ettinger V, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fracture. *Ann Intern Med* 1987;102:319-24.

- bone loss and fracture. Ann Intern Med 1987;102:319-24.
  8 Gallacher JC, Aaron J, Horsman A, Marshall DH, Wilkinson R, Nordin BEC. The crush fracture syndrome in postmenopausal women. Clinical Endocrinology and Metabolism 1973;2: 293-315.
  9 Gallacher JC, Riggs BL, Eisman J, Hamstra A, Arnaud SB, DeLuca HF. Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: effect of age and dietary calcium. J Clin Invest 1979;64:729-36.
  10 Falch JA, Oftebro H, Hang E. Early postmenopausal bone loss is not associated with a decrease in circulating levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, or vitamin D-binding protein. J Clin Endocrinol Metab 1987;64:836-41.
  11 Heaney RP, Recker RR, Saville PD. Calcium balance and calcium requirement in middle aged women. Am 7 Clin Nur 1977;30:1603-11.
- women. Am J Clin Nutr 1977;30:1603-11.
  12 Heaney RP, Recker RR, Saville PD. Menopausal changes in calcium balance performance. J Lab
- Clin Med 1978;92:953-63. 13 Steggerda FR, Mitchell HH. Variability in the calcium metabolism and calcium requirements of
- adult human subjects. J Nutr 1946;31:407-22. 14 Heaney RP, Gallagher JC, Johnston CC, Neer R, Parfitt AM, Whedon GD. Calcium nutrition and
- bone health in the elderly. Am J Clin Nutr 1982;36:986-1013. 15 Hautman DA, Vogel JM, Donaldson CL, Friedman R, Goldsmith RS, Hulley SB. Attempts to
- prevent disuse osteoporosis by treatment with calcitonin, longitudinal compression and supplementary calcium and phosphate. *J Clin Endocrinol Metab* 1973;36:845-58.
- Harrison M, Fraser R, Mullan B. Calcium metabolism in osteoporosis. *Lancet* 1961;i:1015-9.
   Nordin BEC. Osteoporosis and calcium deficiency. *Proc Nutr Soc* 1960;19:129-37.
- Hordin BC, Sotopous and calculation technical and the state of the sta

- Hegsted JM, Moscosco I, Collazos CHC. Study of minimum calcium requirements by adult man. *J Nutr* 1952;46:181-201.
   Riggs BL, Wahner HW, Melton LJ, Richelson LS, Judd HL, O'Fallon WM. Dietary calcium intake and rates of bone loss in women. *J Clin Invest* 1987;80:979-82.
   Stevenson JC, Whitehead MI, Padwick M, et al. Dietary intake of calcium and postmenopausal bartier for a state of the state of the state of the state.
- 22 Stevenson J.C. Wintered MA: Fawk M, et al. Detaily infact of calcium and postnetiopausal bone loss. Br Med J 1988; 297:15-7.
   23 Nilas L, Christiansen C, Rodbro P. Calcium supplementation and postnetiopausal bone loss. Br Med J 1984;289:1103-6.
- 24 Riis B, Thomsen K, Christiansen C. Does calcium supplementation prevent postmenopausal bone loss. N Engl J Med 1987;316:173-7. 25 Christiansen C, Christiansen MS, McNair P, Hagan C, Stocklund E, Transbol I. Prevention of
- rly postmenopausal bone loss controlled 2-year study in 315 normal females.  $Eur \mathcal{J} Clin Invest$ 1980;10:273-9
- 26 Cann CE, Martin MC, Genant HK, Jaffe RB. Decreased spinal mineral content in amenorrheic women. JAMA 1984;251: 262-9.
- wonth, J. J. 1997, 201, 2027.
  27 Drinkware BL, Nilson K, Chesnut CH. Bone mineral content of amenorrheic and eumenorrheic athletes. N Engl J Med 1984;311:277-81.
- 28 Nordin BEC. Calcium balance and calcium requirement in spinal osteoporosis. Am J Clin Nutr 1962;10:384-90.
- 29 Roberts PH, Kerr CH, Ohlson MA. Nutritional status of older women. J Am Diet Assoc 1948;24:292
- 30 Whedon GD, effects of high calcium intakes on bones, blood and soft tissue; relationship of calcium
- 30 whethor OD, effects of mgn calcium intakes on bones, blobd and soft tissue; relationship of calcium intake to balance in osteoporosis. *Federation Proceedings* 1959;18:1112-8.
   31 Ohlson MA, Brewer WD, Jackson L, *et al.* Intakes and retention of nitrogen, calcium and phosphorous by 136 women between ages 30 and 85 years. *Federation Proceedings* 1952;11: 775-83
- 32 Hruxthal LM, Vose GP. The relationship of dietary calcium intake to radiographic bone density in normal and osteoporotic persons. Calc Tissue Res 1969;4:245-56

- 33 Riggs BL, Kelly PJ, Kinney VR, Scholz DA, Bianco AJ. Calcium deficiency in osteoporosis: observations in one hundred sixty-six patients and critical review of the literature. J Bone Joint Surg [Am] 1967;49:915-24.
- 34 Chow R, Harrison JE, Notarius C. Effect of two randomised exercise programmes on bone mass of
- healthy postmenopausal women. Br Med J 1987;295:1441-4.
  Smith RW, Frame B. Concurrent axial and appendicular osteoporosis. Its relation to calcium consumption. N Engl J Med 1965;273:73-8.
  Cheberg L. Ho, C. Covernebing unrividuations in availa actionautoria. J. Part J and Varia Und.
- 36 Chalmers J, Ho KC. Geographical variations in senile osteoporosis. J Bone Joint Surg [Br] 1970:52:667-75
- Hegsted DM. Calcium and osteoporosis. J Nutr 1986;116:2316-9.
   Johnston CC, Norton J, Khairi MRA, et al. Heterogeneity of fracture syndromes in postmeno-pausal women. J Clin Endocrinol Metab 1985;61:551-6.
   Ott SM, Kilcoyne RF, Chesnut CH. Longitudinal changes in bone mass after 1 year as measured by
- different techniques in patients with osteoporsis. Calcif Tissue Int 1986;39:133-8.
  40 Kanis JA, Caulin F, Russell RGG. Problems in the design of clinical trials in osteoporosis. In:
- Dixon ASIJ, Russell RCG, Stamp TCB, eds. Osteoporosis. A multidisciplinary problem. London: Royal Society of Medicine, 1983:205-22. (International Conference Symposium series 55.)
- Kanis JA. Treatment of osteoporotic fracture. Lancet 1984;i: 27-33.
   Schwartz E, Chokas WV, Panariello VA. The effects of high calcium intake in osteoporosis. Am J Med 1964;36:233-49.
- 43 Albanese AA, Edelson AH, Lorenze EJ, Woodhull ML, Wein EH. Problems of bone health in the elderly: ten year study. NY State J Med 1975;75:326-36. 44 Lamke B, Sjoberg HE, Sylven M. Bone mineral content in women with Colles' fracture: effect of
- calcium supplementation. Acta Orthop Scand 1978;49:143-9.
  45 Nordin BEC, Horsman A, Crilly RG, Marshall DH, Simpson M. Treatment of spinal osteoporosis
- in postmenopausal women. Br Med J 1980;280:451-4. 46 Recker RR, Heaney RD. The effect of milk supplements on calcium metabolism, bone metabolism
- and calcium balance. Am J Clin Nutr 1985;41:254-63.
  5 Smith DA, Anderson JJB, Aitken JM, Shimmins J. The effects of calcium supplements of the diet on bone mass measurements. In: Kuhlencordt F, Kruse HP, eds. Calcium metabolism, bone and
- metabolic bone disease. Berlin: Springer, 1975;278-82.
  48 Smith EL, Reddan W, Smith PE. Physical activity and calcium modalities for bone mineral increase in aged women. Med Sci Sports Exerc 1981;13:60-4.
- 49 Lee CJ, Lawler GS, Johnson GH. Effects of supplementation of the diets with calcium rich foods on bone density of elderly females with osteoporosis. Am J Clin Nutr 1981;34:819-23.
- Parfitt AM. Morphological basis of bone mineral measurements: transient and steady state effects of treatment in osteoporosis. *Miner Electrolyte Metab* 1980;4:273-87.
   Falch JA, Odeggard OR, Finnanger AM, Matheson I. Postmenopausal osteoporosis: no effect of
- three years treatment with 1,25-dihydroxycholecalciferol. Acta Med Scand 1987;221: 199-204. 52 Ott SM, Chesnut CH. Calcitriol treatment in patients with postmenopausal osteoporosis. In:
- Christiansen C, Johansen JS, Riis BJ, eds. Osteoporosis. Copenhagen: Osteopress ApS, 1987: 884-9
- 53 Orimo E, Shiraki M, Hayashi T, Nakamura T. Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1α(OH)-vitamin D<sub>3</sub>. Bone and Mineral 1987;3:47-52.
- Senile osteoporosis treated with 10(OH)-vitamin D3, Bone and Mineral 150/354/52.
   Frost HM, Mechanical microdamage, bone remodelling and osteoporosis: a review. In: DeLuca HF, Frost HM, Jee WSS, Johnston CC, Parfitt AM, eds. Osteoporosis: recent advances in pathogenesis and treatment. Baltimore: University Park Press, 1981:185-90.
   Wallace WA. The increasing incidence of fractures of the proximal femur: an orthopaedic University Park Press, 1981:185-90.
- epidemic. Lancet 1983;i:1413-4.
- 56 Bengner U, Johnell O. Increasing incidence of forearm fractures. A comparison of epidemiologic patterns 25 years apart. Acta Orthop Scand 1985;56:158-60. Lewis FA. Fracture of neck of the femur: changing incidence. Br Med J 1981;283:1217-20.
- 58 Falch JA, Ilebekk A, Slungaard U. Epidemiology of hip fractures in Norway. Acta Orthop Scand 1985;56:12-6.
- 59 Cooper C, Barker DJP, Morris J, Briggs RSJ. Osteoporosis, falls and age in fractures of the proximal femur. Br Med J 1987;295:13-5. 60 Aitken JM. Relevance of osteoporosis in women with fracture of the femoral neck. Br Med  $\mathcal{J}$
- 1984;288:597-601
- 61 Riggs BL, Seeman E, Hodgson SF, Taves DR, O'Fallon WM. Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. N Engl J Med 1982;306:446-50
- 62 Aloia JF, Vaswani A, Yeh J, Ellis K, Cohn SH. Treatment of post-menopausal osteoporosis with calcitriol. In: Christiansen C, Johansen JS, Riis BJ, eds. Osteoporosis. Copenhagen: Osteopress ApS, 1987:850-2.
- 63 Gallacher JC, Jerpbak CM, Jee WSS, Johnson KA. Administration of 1,25-dihydroxyvitamin D to patients with postmenopausal osteoporosis. Short and long-term effects on bone and calcium metabolism. *Proc Natl Acad Sci USA* 1982;**79**: 3325-9.
- 64 Ettinger B, Genant HK, Cann CE. Postmenopausal bone loss is prevented by treatment with lowdose estrogen with calcium. Ann Intern Med 1987;106:40-5

### **Richard Packard**

In the issue of the BM7 of 24-31 December 1988 we published an article entitled "Radiotherapy's second setback: promotion of a potentially dangerous treatment by a back door decision.3

In the course of that article it was suggested that Mr Packard had used his influence as the Prime Minister's eye surgeon to have a substantial sum of public money diverted to a form of cancer treatment which we characterised as "a dangerous white elephant."

Mr Richard Packard assures us that he did no such thing and that the decision to allocate £6m of public money towards the installation of a cyclotron at St Thomas's Hospital was made by the ministries concerned following a detailed investigation by them of the merits of cyclotron treatment. We apologise to Mr Packard and the Cyclotron Trust for any suggestion to the contrary.